Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection

by Vandana Singh, Benzinga Editor

October 1, 2021 11:49 AM | 1 min read |

The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's LH combined home collection kit to detect COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age.
The kit will be available at no upfront cost to those who meet clinical guidelines.
Starting in early October, adults 18 and over, as well as parents and guardians of children 2-17 years of age, can request the combined collection kit online through Pixel by Labcorp.
The home collection kit uses the Roche Holdings AG's RHHBY Cobas SARS-CoV-2 & influenza A/B Test on the Cobas 6800/8800 Systems.
Related content: Benzinga's Full FDA Calendar.
Price Action: LH stock is down 0.44% at $280.21 during the market session on the last check Friday.

Posted In: News Health Care FDA General Briefs COVID-19 Coronavirus Diagnostics Health Care Health Care Services

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.